Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | NEK7 | Q8TDX7 | 4/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 3/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.34 |
| ▸ | LCK | P06239 | 2/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 4/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20358435 | 0.89 | BTK (0.48) | BTKLCK | |
| SCHEMBL20358656 | 0.81 | MAP4K1 (0.38) | MAP4K1NTRK1F10FLT3PRKAA1 | |
| SCHEMBL20358443 | 0.79 | BTK (0.48) | BTKLCK | |
| SCHEMBL20359734 | 0.79 | BTK (0.46) | BTKLCK | |
| SCHEMBL20359134 | 0.79 | BTK (0.46) | BTKLCK | |
| SCHEMBL20358478 | 0.79 | BTK (0.61) | BTKLCK | |
| SCHEMBL20359689 | 0.79 | BTK (0.41) | MAP4K1NTRK1BTKIRAK4 | |
| SCHEMBL20359504 | 0.79 | BTK (0.41) | MAP4K1NTRK1BTKIRAK4 | |
| SCHEMBL20358688 | 0.78 | BTK (0.41) | BTKLCK | |
| SCHEMBL20358793 | 0.78 | BTK (0.41) | BTKLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LCK | MAP4K1 324/4885NTRK1 1737/4885F10 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.